Karyopharm Reports Positive Top-Line Phase 2b STORM Results and Reviews the Planned Development Path for Selinexor in Multiple Myeloma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/19/2026

1. NVDA
2. METC
3. SPY
4. DOO
5. HD
6. AMLX
7. ARGX
8. INFQ

Go back to Karyopharm Reports Positive Top-Line Phase 2b STORM Results and Reviews the Planned Development Path for Selinexor in Multiple Myeloma

Baird Maintains Bullish View on Karyopharm Therapeutics (KPTI) Following Positive STORM Results

September 6, 2016 10:08 AM EDT

Baird analyst Michael Ulz reiterated an Outperform rating and $16 price target on Karyopharm Therapeutics (NASDAQ: KPTI) following Phase 2b STORM data, which was positive as expected.

Ulz commented, "Selinexor achieved an overall response rate (ORR) of 20% in penta-refractory multiple myeloma... More